{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:07:26Z","timestamp":1761844046731,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1053\/j.seminhematol.2010.11.008","type":"journal-article","created":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T05:43:28Z","timestamp":1294811008000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities"],"prefix":"10.1053","volume":"48","author":[{"given":"Ola","family":"Landgren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.11.008_bib1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib3","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib4","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.21845","article-title":"IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia","volume":"85","author":"Schuster","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib7","first-page":"3493","article-title":"Idiopathic Bence Jones proteinuria: clinical course and prognosis","volume":"108","author":"Kyle","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0002-9343(73)90172-1","article-title":"Idiopathic Bence Jones proteinuria\u2014a distinct entity?","volume":"55","author":"Kyle","year":"1973","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib10","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/archinte.1988.00380090051014","article-title":"Prognosis of asymptomatic multiple myeloma","volume":"148","author":"Alexanian","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0002-9343(93)90120-E","article-title":"Risk of disease progression in asymptomatic multiple myeloma","volume":"94","author":"Dimopoulos","year":"1993","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.1994.tb04908.x","article-title":"Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma","volume":"87","author":"Witzig","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11864-000-0056-3","article-title":"Smoldering, asymptomatic stage 1, and indolent myeloma","volume":"1","author":"Greipp","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathiesmultiple myelomarelated disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib16","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patients with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib21","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2010.525725","article-title":"Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma","author":"Mailankody","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.11.008_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLML.2010.n.053","article-title":"Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future","volume":"10","author":"Waxman","year":"2010","journal-title":"Clin Lymphoma Myeloma Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310001113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310001113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:27Z","timestamp":1758522087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310001113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0037196310001113"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.11.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}